<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02946554</url>
  </required_header>
  <id_info>
    <org_study_id>HEP101</org_study_id>
    <nct_id>NCT02946554</nct_id>
  </id_info>
  <brief_title>Phase II Safety Study of 2 Dose Regimens of HepaStem in Patients With ACLF</brief_title>
  <acronym>HEP101</acronym>
  <official_title>Multicenter Phase II Safety and Preliminary Efficacy Study of 2 Dose Regimens of HepaStem in Patients With Acute on Chronic Liver Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Promethera Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Promethera Biosciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will assess the safety of different dose regimens of HepaStem in cirrhotic Patients
      with ACLF or with acute decompensation at risk of developing ACLF up to Day 28 of the active
      study period.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2016</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety assessed by occurence of Adverse Events (AE) up to Day 28 of the active study period</measure>
    <time_frame>up to 28Day post first infusion day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy assessed by clinical parameters</measure>
    <time_frame>28Day, 3 month and 1 year post first infusion day</time_frame>
    <description>Clinical efficacy parameters evaluated by mortality, liver transplantation and disease scoring.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy assessed by biological parameters</measure>
    <time_frame>28Day, 3 month and 1 year post first infusion day</time_frame>
    <description>Biological efficacy parameters evaluated by bilirubin, creatinine, INR and albumin values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long term safety Follow up assessed by the occurence of Adverse Event of Special Interest</measure>
    <time_frame>3 month and 1 year post first infusion day</time_frame>
    <description>Adverse Event of Special Interest defined as : SAE (Serious Adverse Event) with fatal</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Acute-On-Chronic Liver Failure</condition>
  <arm_group>
    <arm_group_label>Low dose cohort</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Two dose regimens of HepaStem will be given, which differ in the amount of cells per infusion.
The low dose regimen will be given to the first cohort (first 6 patients included in the study).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose cohort</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The high dose regimen will be given to the second cohort after evaluation of the safety of the 1st cohort (stepwise approach)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HepaStem</intervention_name>
    <arm_group_label>Low dose cohort</arm_group_label>
    <arm_group_label>High dose cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  Diagnosed cirrhosis

          -  Patient with Acute Decompensation of cirrhosis

          -  Serum total Bilirubin ≥ 6 mg/dL (≥100 umol/L)

          -  The INR measurement has to be : 1.2 ≤ INR &lt; 2

        Main Exclusion Criteria:

          -  Absence of portal vein flow

          -  Known or medical history of thrombotic events

          -  Gastrointestinal hemorrhage requiring blood transfusion

          -  Variceal bading or sclerosis within 4 weeks before infusion

          -  Septic shock or non-controlled bacterial infection

          -  Clinical evidence of aspergilus infection.

          -  Circulatory failure

          -  Respiratory disordered

          -  Coagulation disorders defined as INR ≥ 2, Fibrinogen &lt; 100 mg/dL or Platelets &lt;
             50.000/mm3

          -  MELD score &gt; 30.

          -  Major invasive procedure within 4 weeks before infusion

          -  Previous organ transplantation and/or ongoing immunosuppressive treatments.

          -  Renal failure due to chronic kidney disease.

          -  Clinically significant left-right cardiac shunt.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Virginie BARTHEL</last_name>
    <email>virginie.barthel@promethera.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Erasme</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry Gustot, MD</last_name>
    </contact>
    <investigator>
      <last_name>Thierry Gustot, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Brugmann</name>
      <address>
        <city>Bruxelles</city>
        <zip>1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luc Lasser, MD</last_name>
    </contact>
    <investigator>
      <last_name>Luc Lasser, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sven Francque</last_name>
    </contact>
    <investigator>
      <last_name>Sven Francque, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hans VanVlierberghe, MD</last_name>
    </contact>
    <investigator>
      <last_name>Hans VanVlierberghe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>KU Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frederik Nevens, MD</last_name>
    </contact>
    <investigator>
      <last_name>Frederik Nevens, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Liège</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier DETRY</last_name>
    </contact>
    <investigator>
      <last_name>Olivier DETRY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cliniques St Luc</name>
      <address>
        <city>Woluwe-Saint Lambert</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre-Francois Laterre, MD</last_name>
    </contact>
    <investigator>
      <last_name>Pierre-Francois Laterre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Beaujon</name>
      <address>
        <city>Clichy</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francois DURAND, MD</last_name>
    </contact>
    <investigator>
      <last_name>Francois Durand, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Croix Rousse</name>
      <address>
        <city>Lyon</city>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fabien Zoulim</last_name>
    </contact>
    <investigator>
      <last_name>Fabien Zoulim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Paul Brousse</name>
      <address>
        <city>Villejuif</city>
        <zip>94804</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Didier Samuel, MD</last_name>
    </contact>
    <investigator>
      <last_name>Didier Samuel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2016</study_first_submitted>
  <study_first_submitted_qc>October 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2016</study_first_posted>
  <last_update_submitted>November 30, 2017</last_update_submitted>
  <last_update_submitted_qc>November 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute-On-Chronic Liver Failure</keyword>
  <keyword>ACLF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Failure</mesh_term>
    <mesh_term>End Stage Liver Disease</mesh_term>
    <mesh_term>Acute-On-Chronic Liver Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

